Trial Profile
An observational study for incidence of thromboembolism in lung cancer patients, and the evaluation for efficacy and safety of edoxaban in active cancer patients with venous thromboembolism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms Rising-VTE/NEJ037
- 19 Jun 2022 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Results assessing efficacy and safety of direct oral anticoagulants (DOACs) associated with lung cancer chemotherapy, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 28 Sep 2019 Planned End Date changed from 31 May 2021 to 13 Aug 2021.